PHOTO
Dubai: The Ministry of Health and Prevention (MoHAP) hosted the 91st meeting of the Central Gulf Committee for Drug Registration in the Emirate of Dubai, in the presence of His Excellency Dr. Amin Hussein Al Amiri, Assistant Undersecretary for Public Health Policy and Licensing and members of the Central Gulf Committee for Drug Registration.
At the outset of the meeting, HE Dr. Al Amiri conveyed the greetings of His Excellency Abdulrahman Al Owais, Minister of Health and Prevention to the members of the committee.
In his opening remarks, Dr. Al Amiri tackled several essential pillars including; the focus on drug safety and the importance of providing support to the internationally approved drugs by the global drug agencies, particularly, Food and Drug Association (FDA) and European Medicines Agency (EMA).
The other pillars included raising the standards of similar medicines industry across Arab countries and worldwide, in addition to the expeditious completion of innovation and similar medicines registration between the States of the region, as well as the rapid implementation of decisions and directives issued by the Health Ministers’ Council for the GCC States.
Unifying Gulf Efforts in Drug Registration
Dr. Al Amiri further said that GCC recent orientations aim at unifying efforts of providing support to pharmaceutical industry and encouraging local factories to focus on manufacturing innovative medicines, as well as enhancing the confidence of the society in Gulf local pharmaceutical industry.
Also, the meeting discussed the initiatives and approaches which encourage the support of pharmaceutical industry in GCC countries, as well as develop the standards and regulations fostering local and global investment in the pharmaceutical industry through a successful model represented in the UAE in this regard.
A Busy Agenda on Registration of Pharmaceutical Products and Companies
Further to that, the meeting touched on updating the list of central drug registration, as well as updating the Gulf guidance for bioequivalence studies and stability to keep pace with Who’s guides (ICH, USADA). Accordingly, the Saudi Drug & Food Authority has been assigned to update the bioequivalence guidance, as well as Oman, Kuwait and UAE to update the stability guidance considering the ICH requirements.
The meeting also tackled the Guidance for Priority Review of Product Registration including vaccines, cancer medicines, and the registered Gulf drugs in two reference countries, in addition to any other necessary topics the Director of Drug Registration sees they have to be presented to the committee. Those topics may include the participating companies in the unified procurement tenders, mechanism of registration through Verification, registration through Abridged and the mechanism followed in the member states concerning the suspension, withdrawal, and cancellation of products.
One of the meeting agenda items was the mechanism of pharmaceutical products license renewal and review of contact information of the National Pharmacovigilance Centres (NPC) in order to update the medication package insert, then circulate it on the companies according to the committee’s decision. Also, the members considered the approval of Guidance for Graphic Design of Medical Packaging and review of the E-Central Gulf Programme for Central Registration.
© Press Release 2019Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.
The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.
To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.
